Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

Objective THALES demonstrated that ticagrelor plus aspirin reduced the risk of stroke or death but increased bleeding versus aspirin during the 30 days following a mild-to-moderate acute non-cardioembolic ischaemic stroke (AIS) or high-risk transient ischaemic attack (TIA). There are no cost-effecti...

Full description

Bibliographic Details
Main Authors: Yongjun Wang, S Claiborne Johnston, Pierre Amarenco, Carl Mellström, Mario Ouwens, Scott R Evans, Ritika Jain, Stefan James, Hans Denison, Per Ladenvall, Carlos A Molina, Anders Himmelmann, Mikael Knutsson, Amarjeet Tank, Klas Rikner
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:BMJ Neurology Open
Online Access:https://neurologyopen.bmj.com/content/5/2/e000478.full

Internet

https://neurologyopen.bmj.com/content/5/2/e000478.full

Similar Items